

Aripiprazol EQL Pharma approved

The pharmaceutical Aripiprazole EQL Pharma, oral solution 1mg / ml, has been approved by the Swedish Medicines Agency for sale.

Aripiprazole EQL Pharma is a prescription drug used to treat schizophrenia in adults and adolescents from the age of 15 years. Aripiprazole EQL Pharma is also used to treat moderate to severe manic episodes in bipolar disorder.

Aripiprazole EQL Pharma contains aripiprazole, a substance that has been registered as an oral solution in Sweden since 2005. The market for aripiprazole oral solution is limited to approximately SEK 2 million in total annual sales in Sweden.

The product is expected to be launched during the first quarter, 2020.

For more information please contact:

Christer Fåhraeus

CEO EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00

E-mail: christer.fahraeus@eqlpharma.com

Website: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 18 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2020 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 9 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.